1Hironobu Minami,Kenji Kawada,Yasutsuna Sasaki,et al.Population pharmacokinetics of docetaxel in patients with hepatic dysfunction treated in an oncology practice.Cancer Sci,2009,100(1):144-9.
2Slaviero KA,Clarke SJ,Mclachlan AJ,et al.Population pharmacokinetics of weekly docetaxel in patients with advanced cancer.Br J Clin Pharmacol,2003,57(1):44-53.
3Joerger M,Huitema ADR,Huizing MT,et al.Safety and pharmacology of paclitaxel in patients with impaired liver function:a population pharmacokinetic-pharmacodynamic study.Br J Clin Pharmacol,2007,64(5):622-33.
4Dobbs NA,Twelves CJ,Gregory W,et al.Epirubicin in patients with liver dysfunction:development and evaluation of a novel dose modi?cation scheme.Eur J Cancer,2003,39:580-86.
5Ralph LD,Thomson AH,Dobbs NA,et al.A population model of epirubicin pharmacokinetics and application to dosage guidelines.Cancer Chmother Pharmacol,2003,52(1):34-40.
6Benjamin RS,Wiernik PH,Bachur NR.Adriamycin chemotherapy efficacy,safety,and pharmacologic basis of an intermittent single high-dosage schedule.Cancer,1974,33:19-27.
